pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,189 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1787Endpoints1391Fierce Biotech711BioSpace702BioPharma Dive526raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12335Rare Disease3228Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • Anthropic expands rare disease collaborations as Novo sues Lilly and Agios halts sickle cell drug
    Anthropic, a biotech firm, announced it is expanding its partnership portfolio focused on rare disease therapeutics, deepening collaborations with several companies to advance pipeline candidates.…
    STAT · 3mo agoDealNeutral↗ source
  • Novo Nordisk sues Eli Lilly over allegedly deceptive obesity and diabetes ads
    Novo Nordisk has filed a federal lawsuit against Eli Lilly, accusing the rival of running misleading advertisements for its obesity and diabetes medicines. The company claims Lilly's ads rely on ou…
    STAT · 3mo agoRegulatoryNegative↗ source
← prev
page 83 of 128
next →
111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1062
Pain778
Endocrinology & Metabolism777
Nephrology762
  • Novo Nordisk sues Eli Lilly, alleging deceptive ads that misrepresent GLP-1 drug efficacy
    Novo Nordisk filed a lawsuit in federal court in New Jersey accusing Eli Lilly of running a deceptive advertising campaign. The complaint says Lilly’s ads compare the highest doses of its weight‑l…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Jupiter Neurosciences signs $100M deal for U.S. rights to PharmAla's MDMA therapy ALA-002
    Jupiter Neurosciences announced a licensing agreement with Canadian biotech PharmAla Biotech to obtain U.S. rights to an MDMA‑based drug, ALA‑002, aimed at treating neuropsychiatric conditions. Th…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • Rare-disease biotech coalition urges Trump admin to carve out orphan drugs from Medicare price-cut pilots
    Biotech firms formed the Rare Disease Company Coalition and met with the White House Office of Management and Budget to discuss excluding orphan drugs from two Medicare price‑cut pilot programs. T…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Novartis halts phase-2 radioligand therapy Lu-NeoB after disappointing data, but reaffirms commitment to RLT
    Novartis announced it is halting development of Lu-NeoB, a gastrin-releasing peptide receptor-targeting radioligand therapy, after phase-2 data failed to demonstrate sufficient efficacy. The candi…
    Fierce Biotech · 3mo agoNegative readoutNegative↗ source
  • Lupin spins out two phase-1 cancer candidates into US startup Kaveri, taking majority stake and providing seed funding
    Lupin, an Indian generics manufacturer, has created a U.S.-based spinout called Kaveri Therapeutics by transferring two clinical-phase cancer drug candidates. The assets are a PRMT5 inhibitor (LNP…
    Fierce Biotech · 3mo agoDealNeutral↗ source
  • Ashlins Pharma licenses interferon alpha-2b from Lee's, eyes $50M raise to pursue FDA approval for rare disease
    Ashlins Pharmaceuticals has signed a licensing agreement with Hong Kong‑based Lee’s Pharmaceutical to obtain the ex‑China rights to a Chinese formulation of interferon alpha‑2b. The deal, announced…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • Rare disease drugmakers brace for potential Trump administration price cuts amid GOP push on health‑care fraud
    Rare disease drugmakers are watching the Trump administration closely as proposals emerge that could force lower prices for their specialty therapies. The companies are exploring strategies to miti…
    STAT · 3mo agoRegulatoryNeutral↗ source
  • Dimension raises $800 million for third fund to boost AI-driven biotech ventures
    Dimension, a venture capital firm focused on the intersection of technology and biotech, announced the closing of its largest fund to date, raising $800 million for its third fund, called Dimension…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Advocates warn federal HIV prevention funding cuts could force community groups to close
    Community-based organizations that deliver HIV testing and prevention tools are urging federal health officials to restore a key funding program that recently expired. Advocates say the lapse thre…
    STAT · 3mo agoRegulatoryNegative↗ source
  • ‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
    For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is en…
    Fierce Biotech · 3mo agoDealNeutral↗ source
  • THC-infused drinks found on New York shelves near schools, often sold without ID and breaching state law
    A variety of cannabis-infused beverages are now stocked in grocery stores, bodegas and delis across New York City. Brands such as Oasis, Cann, Milonga, Cycling Frog, Tempters, Gigli and Mighty Kind…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Proposed OMB Rule Threatens NIH Grant Independence, Experts Warn
    The Office of Management and Budget has issued a proposed rule that would require political appointees to review NIH research grants and certify that the projects "demonstrably advance the Presiden…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Roche appoints Dan Malarek as President and CEO of Diagnostics North America, creates new CCO role
    Roche announced that Dan Malarek, who has led Foundation Medicine since 2023, will become President and CEO of Roche Diagnostics North America. Malarek, a 19‑year veteran of Roche, will succeed Br…
    Fierce Biotech · 3mo agoPositive↗ source
  • Trump administration defers over $1 billion in Medicaid payments to California and Minnesota over fraud concerns
    The Trump administration announced it is holding back more than $1 billion in Medicaid funds for California and Minnesota, saying the states have suspected fraud and non‑compliance. Health Secreta…
    STAT · 3mo agoRegulatoryNegative↗ source
  • Urologist warns that Defense Dept's testosterone screening for servicemembers fuels outdated masculinity myths
    Dr. Elizabeth Dray, a urologist, criticizes Defense Secretary Pete Hegseth's recent plan to screen all service members aged 30 and older for testosterone, describing it as a modern echo of ancient…
    STAT · 3mo agoNegative↗ source
  • Epic Systems sees senior leadership exits amid speculation of broader exodus
    Epic Systems is experiencing notable executive turnover, highlighted by the recent departure of President Sumit Rana, who had been expected to succeed CEO Judy Faulkner. Rana told a reporter last…
    STAT · 3mo agoNegative↗ source
  • Nabla appoints former Bamboo Health president Brian Manning as CEO to boost US market push
    Nabla, the Paris‑based maker of ambient AI scribes for clinical documentation, announced that Brian Manning will take over as chief executive officer. Manning comes from a background in care‑coord…
    STAT · 3mo agoNeutral↗ source
  • Right-wing groups intensify campaign to limit abortion pills amid ongoing health news
    Advocates on the political right are renewing efforts to restrict access to medication abortions, according to the latest Morning Rounds newsletter. The piece notes that the campaign is gaining mom…
    STAT · 3mo agoNegative↗ source
  • Opinion warns post-pandemic polarization may lock in false lessons from Covid response
    The authors, Marc Lipsitch and Sara Cody, argue that the public and policymakers are drawing misleading conclusions from the Covid-19 pandemic. They point out that early nonpharmaceutical interven…
    STAT · 3mo agoNegative↗ source
  • Crystalys mines $130M series B to push gout drug through phase 3
    Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.
    Fierce Biotech · 3mo agoNeutral↗ source
  • Tempus acquires Personalis for $1.5 billion to expand cancer genomics and MRD testing
    Tempus announced it will purchase Personalis in a transaction valued at $1.5 billion, giving it full ownership of the cancer‑genomics firm. The deal builds on a 2023 partnership where Tempus inves…
    Fierce Biotech · 3mo agoDealPositive↗ source
  • Tempus AI to buy cancer test maker Personalis for $1.5 billion
    Tempus AI announced it will acquire Personalis, a California-based company that offers a molecular residual disease test for cancer, in a transaction valued at $1.5 billion. The deal, priced at $1…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Medicare proposes cuts to hospital payments for drugs and imaging under new outpatient rule
    Medicare's Centers for Medicare & Medicaid Services released a proposed rule that would lower the amounts hospitals receive for certain prescription drugs and imaging services provided to Medicare…
    STAT · 3mo agoRegulatoryNegative↗ source